PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jrsocmedLink to Publisher's site
 
J R Soc Med. 1991 February; 84(2): 63–65.
PMCID: PMC1293085

Prospects for the treatment of multiple sclerosis.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (716K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Wynn DR, Rodriguez M, O'Fallon WM, Kurland LT. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology. 1990 May;40(5):780–786. [PubMed]
  • Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report. Neurology. 1970 May;20(5):1–59. [PubMed]
  • Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry. 1987 May;50(5):511–516. [PMC free article] [PubMed]
  • Thompson AJ, Kennard C, Swash M, Summers B, Yuill GM, Shepherd DI, Roche S, Perkin GD, Loizou LA, Ferner R, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology. 1989 Jul;39(7):969–971. [PubMed]
  • Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, Kroin JS. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989 Jun 8;320(23):1517–1521. [PubMed]
  • Bever CT, Jr, Leslie J, Camenga DL, Panitch HS, Johnson KP. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann Neurol. 1990 Apr;27(4):421–427. [PubMed]
  • Ormerod IE, Miller DH, McDonald WI, du Boulay EP, Rudge P, Kendall BE, Moseley IF, Johnson G, Tofts PS, Halliday AM, et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain. 1987 Dec;110(Pt 6):1579–1616. [PubMed]
  • Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA, Weiner HL. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983 Jan 27;308(4):173–180. [PubMed]
  • Cook SD, Devereux C, Troiano R, Hafstein MP, Zito G, Hernandez E, Lavenhar M, Vidaver R, Dowling PC. Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet. 1986 Jun 21;1(8495):1405–1409. [PubMed]
  • Cook SD, Troiano R, Zito G, Rohowsky-Kochan R, Sheffit C, Dowling PC, Devereux CK. Deaths after total lymphoid irradiation for multiple sclerosis. Lancet. 1989 Jul 29;2(8657):277–278. [PubMed]
  • Rudge P, Koetsier JC, Mertin J, Mispelblom Beyer JO, Van Walbeek HK, Clifford Jones R, Harrison J, Robinson K, Mellein B, Poole T, et al. Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989 May;52(5):559–565. [PMC free article] [PubMed]
  • Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med. 1985 Jan 21;78(1A):44–49. [PubMed]
  • Soulillou JP, Cantarovich D, Le Mauff B, Giral M, Robillard N, Hourmant M, Hirn M, Jacques Y. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med. 1990 Apr 26;322(17):1175–1182. [PubMed]
  • Heber-Katz E, Acha-Orbea H. The V-region disease hypothesis: evidence from autoimmune encephalomyelitis. Immunol Today. 1989 May;10(5):164–169. [PubMed]
  • Acha-Orbea H, Mitchell DJ, Timmermann L, Wraith DC, Tausch GS, Waldor MK, Zamvil SS, McDevitt HO, Steinman L. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell. 1988 Jul 15;54(2):263–273. [PubMed]
  • Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell. 1989 Oct 20;59(2):247–255. [PubMed]
  • Urban JL, Horvath SJ, Hood L. Autoimmune T cells: immune recognition of normal and variant peptide epitopes and peptide-based therapy. Cell. 1989 Oct 20;59(2):257–271. [PubMed]
  • Hartung HP, Schäfer B, Heininger K, Stoll G, Toyka KV. The role of macrophages and eicosanoids in the pathogenesis of experimental allergic neuritis. Serial clinical, electrophysiological, biochemical and morphological observations. Brain. 1988 Oct;111(Pt 5):1039–1059. [PubMed]
  • Brown JR, Beebe GW, Kurtzke JF, Loewenson RB, Silberberg DH, Tourtellotte WW. The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Neurology. 1979 Sep;29(9 Pt 2):3–23. [PubMed]
  • McKhann GM. The trials of clinical trials. Arch Neurol. 1989 Jun;46(6):611–614. [PubMed]
  • Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology. 1990 Jun;40(6):971–975. [PubMed]
  • Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: a critique. Neurology. 1988 Nov;38(11):1793–1798. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press